Meeting
2022 ASCO Annual Meeting
Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML).
Presenter
Faustine Ong, MD
The University of Texas MD Anderson Cancer Center, Department of Leukemia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7038)
DOI
10.1200/JCO.2022.40.16_suppl.7038
Abstract #
7038
Poster Bd #
269
Abstract Disclosures
Similar Videos & Slides
Speaker: Eileen Mary O'Reilly, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Speaker: Patrick Hagen, MD, MPH
Videos & Slides
2023 ASCO Annual Meeting
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Speaker: Sujay A. Vora, MD
Videos & Slides
2023 ASCO Annual Meeting
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
Speaker: Matthew Joseph Wieduwilt, MD, PhD